Investing.com's InvestingPro Fair Value model identified Haemonetics (NYSE: HAE) as a compelling opportunity, and the stock subsequently delivered a 64% return, according to the platform's own analysis published August 1, 2026. The call draws attention to how quantitative fair-value estimates can align with — and occasionally anticipate — significant price moves in mid-cap medical technology names.
Haemonetics shares traded at $85.42 on July 29, 2026, up 3.5% on the day and 44.8% over the prior three months. The stock's 52-week range spans $47.32 to $87.32, placing the current price near the upper bound. Market capitalization stood at $3.88 billion, with a price-to-earnings ratio of 41.47x.
Fundamental results for fiscal year 2026 (ended March 28, 2026) show revenue of $1.33 billion and net income of $97.31 million. Diluted earnings per share came in at $2.05, down from $3.31 in the prior year.
The Plasma segment returned to growth in the fourth quarter of fiscal 2026, with revenue of $130 million, up 3% reported and 13% organic excluding CSL. U.S. plasma collection share grew in the high single digits, while Europe posted double-digit growth.
Valuation metrics have expanded sharply. The P/E ratio reached 38.64 as of July 16, 2026, an 83% increase over the trailing 12-month average of 21.11. Year-end P/E for 2026 stands at 38.64, up 65% from 23.38 at the end of 2025. Peer comparison places Haemonetics at a P/E of 37.52 versus larger med-tech names such as Medtronic (21.73) and Boston Scientific (18.16).